Physician profile
Lawrence C Stines
NPI 1306822978
$12,189.87
in general payments reported to CMS, 2019-2025
43 companies · $2,956 in 2025
The $2,956 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,579 · 2022: $2,348 · 2023: $2,445 · 2024: $2,862 · 2025: $2,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,101 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,100.86 |
| Education | $161.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,715.27 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,401.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,139.74 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $953.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $876.32 | 2021-2025 | Korlym |
| Pfizer INC. | $716.17 | 2023-2025 | |
| Abbvie INC. | $624.77 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $617.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.74 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Axsome Therapeutics, INC. | $380.96 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $319.49 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $281.36 | 2021-2025 | Veozah |
| Gilead Sciences, INC. | $280.30 | 2025 | Epclusa, Livdelzi |
| Sanofi-Aventis U.S. LLC | $230.48 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $225.52 | 2021-2025 | Recorlev |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $215.69 | 2022 | |
| Amgen INC. | $209.14 | 2021-2025 | Otezla, Repatha, Repatha |
| Horizon Therapeutics Plc | $151.56 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $129.18 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $88.49 | 2022-2024 | Eliquis |
| Eisai INC. | $88.17 | 2021-2022 | |
| Melinta Therapeutics, LLC | $87.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.80 | 2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $81.30 | 2021 | |
| Antares Pharma, INC. | $74.95 | 2025 | Xyosted |
| Exact Sciences Corporation | $71.61 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kyowa Kirin, INC. | $64.94 | 2024-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $64.31 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $58.04 | 2021-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $56.33 | 2022-2025 | |
| Radius Health, INC. | $53.62 | 2021-2024 | Tymlos |
| Optinose US, INC. | $44.77 | 2024 | |
| Arbor Pharmaceuticals, INC. | $35.64 | 2021 | |
| Amarin Pharma, INC. | $34.76 | 2021 | |
| Genentech USA, INC. | $34.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.11 | 2024-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $22.36 | 2025 | Nexletol |
| Hikma Pharmaceuticals USA | $22.33 | 2022 | |
| Alvogen INC | $20.23 | 2021 | |
| Boston Scientific Corporation | $19.47 | 2023 | |
| Dexcom, INC. | $18.45 | 2025 | Dexcom G6 Transmitter |
| Vivus LLC | $17.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Stines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.